Skip to main content
SpringerLink
Log in

Update zu Therapien mit Organschutzfaktor

Orale Antidiabetika bei Typ-2-Diabetes

  • Fortbildung_CME
  • Published:
Info Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. McAllister DA. Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3,25 Million People With and Without Diabetes Mellitus. Circulation. 2018; 138(24),2774-86

  2. Davies MJ et al. Management of hyperglycaemia in type 2 diabetes - A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61,2461-98

  3. Cosentino F et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ. European Heart Journal 2020;41(2):255-323

  4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359,1577-89

  5. Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014:371,1547-8

  6. Aroda VR et al. Diabetes Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101,1754-61

  7. UK Prospective Diabetes Study (UKPDS) Group. UKPDS Study. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352,854-65

  8. Griffin SJ et al. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trails among people with type 2 diabetes. Diabetologia 2017;60,1620-9

  9. Mallik R et al. Metformin in cancer. Diabetes Res Clin Pract 2018;143,409-19

  10. Tseng CH. Metformin reduces risk of benign goiter in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2019;180,365-72

  11. Monami M et al. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of. Diabetes Obes Metab. 2018;20,5,1213-22

  12. Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380 347-57

  13. Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393,10166,31-9

  14. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373,2117-28

  15. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381,1995-2008

  16. Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380,24, 2295-306

  17. Heerspink HJL. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383,1436-46

  18. Gerstein HC. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394,121-30

  19. Husain M. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381,841-51

  20. Rosenstock J et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA. 2019;322,12,1155-66

  21. Ling J et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetologca 2019;56,249-72

  22. Rosenstock J. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA 2019;321,69-79

  23. Buse JB et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63,221-8

Download references

Author information

Authors and Affiliations

  1. Innere Medizin II – Diabetologie und Endokrinologie, St. Vinzenz Hospital Köln, 50733 Köln, Deutschland

    Monica Negrean

Authors
  1. Monica Negrean
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica Negrean.

Ethics declarations

Die Autorin erklärt: Forschungsförderung: keine; Honorare, Kostenerstattung: Boehringer Ingelheim, Forum für medizinische Fortbildung, Ipsen, Lilly, Medifora, Novo Nordisk, Sanofi; Beratertätigkeit: Boehringer Ingelheim; Patent/Geschäftsanteile/Aktien: keine

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Negrean, M. Orale Antidiabetika bei Typ-2-Diabetes. Info Diabetol 14, 28–39 (2020). https://doi.org/10.1007/s15034-020-2209-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15034-020-2209-8

Search

Navigation